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Abstract
Purpose This analysis determined the incidence of seri-
ous rhabdomyolysis events reported during trabectedin
treatment since the ﬁrst phase I clinical trial in April 1996
up to September 2010.
Methods Search was done in the Yondelis
 Pharmaco-
vigilance and Clinical Trials databases using a list of terms
according to the Medical Dictionary for Regulatory
Activities (MedDRA, v. 13.1), followed by a medical
review of all cases retrieved. Total estimated sample was
10,841 patients: 2,789 from clinical trials; 3,926 from
compassionate use programs; and 4,126 treated in the mar-
ketplace. Two groups were identiﬁed: (1) rhabdomyolysis
and (2) clinically relevant creatine phosphokinase (CPK)
increases without acute renal failure (ARF). Descriptive
analysis included demographic, clinical/laboratory data,
and contributing/confounding factors. Potential predictive
factors were evaluated by multivariate stepwise logistic
regression analysis. Possible changes of pharmacokinetics
(PK) in patients with rhabdomyolysis were explored using a
population PK model.
Results The global incidence of rhabdomyolysis was
0.7 %, and most cases occurred in Cycle 2 of treatment.
The incidence of fatal cases was 0.3 %. None of the vari-
ables evaluated to detect potential risk factors of rhabdo-
myolysis were predictive. Additionally, CPK increases
(without ARF) were detected in 0.4 % of patients as an
incidental ﬁnding with good prognosis.
Conclusions Rhabdomyolysis is an uncommon event
during trabectedin treatment. Multivariate analyses did not
show any potential factor that could be predictive or rep-
resent a signiﬁcantly higher risk of developing rhabdo-
myolysis. Nevertheless, close patient monitoring and
adherence to drug administration guidelines may help to
limit the incidence of this event.
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Introduction
Trabectedin (Yondelis
) is a marine-derived anticancer
agent approved in 2007 as a single agent in the European
Union for the treatment of soft tissue sarcoma (STS) after
failure of standard-of-care chemotherapy (doxorubicin and/
or ifosfamide) or for patients unsuited to receive these
agents [9], and in 2009 for treatment of patients with
relapsed, platinum-sensitive ovarian cancer in combination
with pegylated liposomal doxorubicin (PLD; Caelyx
)
[16]. Rhabdomyolysis has been reported as an uncommon
adverse reaction associated with trabectedin treatment
[2, 20, 22, 24]. Its etiology was unclear [12], as rhabdo-
myolysis was not observed during preclinical studies: only
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was found in repeat-dose studies in Cynomolgus monkeys,
with no macro- or microscopic ﬁndings suggestive of tra-
bectedin-induced rhabdomyolysis.
Rhabdomyolysis is an injury of skeletal muscle that
releases potentially toxic muscle cell components (e.g.,
myoglobin, other intracellular proteins, and electrolytes)
into the extracellular ﬂuid and blood stream, which may
result in renal damage [1, 21]. Rhabdomyolysis may have a
number of causes, including direct trauma, excessive
muscular activity, body-temperature extremes, muscle
hypoxia, infections, metabolic and electrolyte disorders,
endocrine disorders, connective tissue disorders, drugs, and
toxins. Overall, the clinical features of rhabdomyolysis are
quite variable and they can be summarized as muscular
signs and symptoms (pain, weakness, tenderness, and
contractures) and other symptoms (malaise, fatigue, fever,
tachycardia, nausea, and vomiting). Rhabdomyolysis can
result in life-threatening renal and multi-organ failure with
hypovolemia, hyperkalemia, metabolic acidosis, dissemi-
nated intravascular coagulation, and compartment syn-
drome, secondary arrhythmias, or cardiac arrest [7, 14].
Biochemically, rhabdomyolysis is deﬁned by marked blood
CPK elevation [typically greater than 10 times the upper
limit of normal (ULN)] with creatinine increase [6, 17].
CPK elevation is the most sensitive marker for skeletal
muscle injury [5].
The aim of this analysis is to provide an updated and
comprehensive summary of rhabdomyolysis events during
treatment with trabectedin in adult patients with advanced
solid tumors both as single agent or in combination with
doxorubicin or PLD. Furthermore, we tried to identify
potential predictive risk factors for this event.
Materials and methods
The period analyzed was from the beginning of the ﬁrst
phase I clinical trial in April 1996 up to 17 September
2010, with a total estimated sample of 10,841 treated
patients: 2,789 in clinical trials; 3,926 in compassionate use
programs; and an estimation of 4,126 in the marketplace.
A search was carried out in both the Yondelis
 Phar-
macovigilance and the Clinical Trials databases using a list
of terms according to the Medical Dictionary for Regula-
tory Activities (MedDRA, v. 13.1). The preferred terms
(PTs) of the standardized MedDRA query (SMQ) for
rhabdomyolysis were used, as well as PTs from other
MedDRA System Organ Class (SOCs) that could be related
to rhabdomyolysis, or to the adverse events associated with
trabectedin treatment. A medical review was performed for
all cases retrieved, and 2 groups were identiﬁed: (1)
rhabdomyolysis and (2) clinically relevant CPK increases
without acute renal failure (ARF). The criteria for allo-
cating a case to the rhabdomyolysis group were the fol-
lowing: cases reported as rhabdomyolysis, and cases with
increased CPK (any grade) plus ARF, with or without
symptoms of rhabdomyolysis or other diagnostic criteria
[17]. The criteria for allocating a case to the CPK increases
without ARF group were the following: CPK increases
recorded as serious adverse events (any grade) in the
Pharmacovigilance database, and CPK increases recorded
as severe (grades 3 or 4) and with normal renal function or
without available data on renal function in the Clinical
Trials database. A descriptive analysis of these 2 groups of
cases is shown here, including the main demographic,
clinical and laboratory data, as well as contributing/con-
founding factors for rhabdomyolysis. All published cases
of rhabdomyolysis with trabectedin up to the cutoff date for
this analysis are included in the current assessment.
Potential predictive risk factors for rhabdomyolysis
were explored. This analysis was performed in 2,321
patients treated in clinical trials from which all data nec-
essary for cases and controls were available. Multivariate
logistic regressions with stepwise variable selection were
used to evaluate the possible relationship between the
occurrence of rhabdomyolysis and categorical/continuous
variables such as demography, previous medical history,
concomitant treatments, indication for treatment, dose, and
laboratory data of clinical interest.
The potential inﬂuence of trabectedin pharmacokinetic
(PK) parameters in patients who developed rhabdomyoly-
sis in clinical trials was explored using a population PK
model [19]. Brieﬂy, this open 4-compartment PK model
consisted of a central plasma compartment and 3 peripheral
compartments. Trabectedin was assumed to have linear and
non-linear distribution from the central to the deep and
shallow peripheral compartments, respectively. The model
also included a catenary compartment representing a tissue
compartment off the shallow peripheral compartment. The
model was updated with the data from 900 patients with
available PK data achieving parameters very similar to
those already published. Multivariate logistic regression
was used to evaluate the relationship between the occur-
rence of rhabdomyolysis and the main PK variables:
clearance (CL), maximum plasma concentration (Cmax),
and area under the curve (AUC) calculated from CL and
dose administered.
Results
Rhabdomyolysis during treatment with trabectedin
Seventy-ﬁve of an estimated number of 10,841 treated
patients had rhabdomyolysis (incidence of 0.7 %) (Table 1);
1558 Cancer Chemother Pharmacol (2012) 69:1557–1565
123these cases occurred in clinical trials (n = 26; incidence of
0.9 %), compassionate use programs (n = 26; 0.7 %), and
in the marketplace (n = 23; 0.6 %).
Approximately half of these 75 patients (45.3 %) had
one or more of the following contributive factors: incorrect
posology; previous or concomitant liver disorders with
potential effect on the drug metabolism; concomitant
treatments (CYP3A4 inhibitors; other drugs known to
produce rhabdomyolysis), and other rhabdomyolysis eti-
ologies (Table 2).
The median age of patients with rhabdomyolysis was
55 years (range 21–83 years), and 41 of them (54.7 %)
were females (Table 1). Most trabectedin clinical trials
were conducted in patients with STS and ovarian cancer
(958 and 687 of 2,321 treated patients with data on case/
controls, respectively). Compassionate use programs were
conducted in STS (3,929 patients), and STS and ovarian
cancer are approved indications for trabectedin (*3,713
patient with STS and 413 patients with ovarian cancer of
4,126 treated patients in the marketplace). Therefore, the
majority of patients who developed rhabdomyolysis were
treated for STS (n = 65) at the dose approved for this
indication 1.5 mg/m
2 every 3 weeks (q3wk), followed by
patients treated for ovarian cancer (n = 6), which is the
second approved indication at the corresponding dose and
schedule 1.1 mg/m
2 q3wk. Nevertheless, the incidence of
rhabdomyolysis in STS and ovarian cancer was similar.
Rhabdomyolysis was reported as related to trabectedin
treatment in 93.4 % of cases (Table 3).
The majority of cases were reported in Cycle 2 of
trabectedin administration (n = 43; 57.3 %), and cases
from Cycle 4 onwards were rare (n = 6; 8.0 %) (Table 3).
Table 1 Cases of rhabdomyolysis and creatine phosphokinase increases (without acute renal failure) during treatment with trabectedin in cancer
patients: demographic data
Total of cases
(patients)
Rhabdomyolysis CPK increases (without ARF)
a
n = 75/10,841
b 0.7 % n = 48/10,841
b 0.4 %
Age (years)
c
Median 55 58
Range 21–83 14–80
Gender (n,% )
c
Male 32 42.7 % 20 41.7 %
Female 41 54.7 % 27 56.3 %
Unknown 2 2.7 % 1 2.1 %
Indication n/Total treated
d % n/Total treated
d %
Bone sarcoma – – 2/280 0.7
Breast cancer – – 2/285 0.7
Endometrial cancer 2/65 3.1 – –
Ovarian cancer 6/1,240 0.5 11/1,240 0.9
Soft tissue sarcoma 65/8,784 0.7 31/8,784 0.4
Unknown 2 – 2 –
Cutoff, September 17, 2010
The 75 patients with rhabdomyolysis were distributed among 15 different countries: Austria (n = 1), Belgium (n = 3), Brazil (n = 1), Canada
(n = 4), China (n = 1), France (n = 7), Germany (n = 7), Greece (n = 1), India (n = 1), Italy (n = 5), Russia (n = 2), Spain (n = 11),
Sweden (n = 1), United Kingdom (n = 7), and the USA (n = 23)
The 48 patients with CPK increases without ARF were distributed among 13 different countries: Brazil (n = 3), Canada (n = 3), France (n = 5),
Germany (n = 1), Hong Kong (n = 1), Italy (n = 3), Korea (n = 1), Poland (n = 1), Russia (n = 1), Spain (n = 1), Sweden (n = 1), United
Kingdom (n = 4), and the USA (n = 23)
ARF acute renal failure, CPK creatine phosphokinase, NCI-CTCAE National Cancer Institute Common Toxicity Criteria for Adverse Events
a CPK increases (without acute ARF) reported as serious adverse events (any grade) in the Pharmacovigilance database, or as severe (grade 3 or
4 according to NCI-CTCAE) in the Clinical Trials database
b The total number of patients treated in clinical trials, compassionate use, and in the marketplace estimate were 2,789, 3,926 and 4,126,
respectively, for an approximate total number of 10,841 treated patients
c Data are shown for the 75 patients with rhabdomyolysis and the 48 patients with 58 CPK increases without ARF
d Based on rough estimate of total treated patients. The total estimate of 10,841 patients evaluated in this analysis also includes patients treated in
other indications (e.g., lung, melanoma, etc.) in which rhabdomyolysis was not reported
Cancer Chemother Pharmacol (2012) 69:1557–1565 1559
123The median day for CPK peak in rhabdomyolysis cases
was Day 13.5 after last dose (range 2.0–33.0), and grade
3/4 CPK occurred in 33.3 % of patients.
Well-known adverse reactions associated with trabect-
edin treatment were identiﬁed as concomitant to rhabdo-
myolysis: neutropenia (any grade) in 70.7 % of the cases
and liver function test alterations (any grade) in 66.7 % of
the cases (Table 3).
Dialysis was performed in 20 cases (26.7 %) to treat the
event (Table 3). In the remaining cases, corrective treat-
ment usually consisted of intravenous hydration and
occasionally urine alkalinization.
The prognosis of rhabdomyolysis depends on its early
diagnosis and prompt management. In this series, 31 cases
had a fatal outcome (incidence of 0.3 % with respect to the
overall population of 10,841 patients). The time from onset
of symptoms until diagnosis was not usually provided.
Dialysis was performed in 12 (38.7 %) of the fatal cases,
and not performed in 14 of them (45.2 %), in some cases
due to end stage of the underlying malignancy or patient
refusal (information was not provided in the other 5 fatal
cases). Dialysis was not started at the time of diagnosis in 6
of the 12 fatal cases in which it was performed, being
started only after clinical or laboratory deterioration (oli-
guria, anuria, metabolic acidosis, or important CPK ele-
vation with respect to that at diagnosis).
Cases of CPK increase without acute renal failure
during treatment with trabectedin
Forty-eight of an estimated number of 10,841 treated
patients (incidence of 0.4 %) (Table 1) had 58 events of
clinically relevant CPK increase without ARF. Distribution
by grade was as follows: grade 2, 5.2 %; grade 3, 43.1 %;
grade 4, 34.5 %, and unknown grade, 17.2 %. All patients
had normal renal function and no relevant clinical impact.
Cardiac events were ruled out as a cause of CPK elevation.
Muscular symptoms were present in only 13 patients
(27.1 %), and important muscular effort during treatment
was reported as a confounding factor in 2 patients.
The median age of these 48 patients was 58 years (range
14–80 years), and 27 of them (56.3 %) were females. Most
cases were reported in patients treated for STS and ovarian
cancer (n = 31 and n = 11, respectively), which are the 2
most evaluated indications for trabectedin, and 35 cases
(60.3 %) occurred in the q3wk regimens (Table 3).
About half of these CPK increases occurred during the
ﬁrst 3 cycles of trabectedin (n = 27; 46.6 %) (Table 3).
The median day for CPK peak was Day 18.0 after last
cycle administration (range 2.0–34.0).
With respect to concomitant adverse reactions of tra-
bectedin, neutropenia and liver function test alterations
(any grade) were present in 43.1 and 51.7 % of the CPK
increases without ARF, respectively (Table 3).
No patient required dialysis and the prognosis was
generally good: 70.7 % of CPK increases recovered, 5.2 %
did not recover at the moment of the report, and informa-
tion was not provided in 24.1 % (Table 3).
Multivariate analysis of cases of rhabdomyolysis
from clinical trials
Twenty cases of rhabdomyolysis were observed in 2,321
patients treated in clinical trials with data of controls
(patients included in clinical trials who did not develop
Table 2 Possible contributing factors found in patients with rhab-
domyolysis during treatment with trabectedin in cancer patients
n = 75
a %
Incorrect treatment posology
No reduction of dose when required 2 2.6
No delay of the cycle when required 1 1.3
Dose was increased with respect to that of previous
cycle
b
1 1.3
Possible effect on hepatic metabolism of the drug
History of hepatic disorders (cirrhosis; chronic
hepatitis C)
2 2.6
Hepatic metastases 5
c 6.7
Acute hepatic disorder (portal vein thrombosis) 1 1.3
Important usual alcohol consumption 1 1.3
Concomitant administration of CYP3A4 inhibitors
Amiodarone 2 2.6
Aprepitant 1 1.3
Clarithromycin 2 2.6
Diltiazem 1 1.3
Lercanidipine 1 1.3
Verapamil 2 1.3
Other confounding factors
Concomitant statins (atorvastatin) 2 2.6
Concomitant Sinemet
 (carbidopa/levodopa)
d 1 1.3
Hypothyroidism 4 5.3
Muscular trauma 1 1.3
Sepsis 5 6.7
Severe pneumonia 5 6.7
Cutoff, September 17, 2010
a Data are shown for the 75 patients with rhabdomyolysis. Patients
could have more than one contributive factor
b Not allowed in the Summary of Product Characteristics of
trabectedin
c All 5 patients with hepatic metastases were treated in clinical trials.
Bulky (C5 cm) liver metastases were found in 2 of these 5 patients.
The incidence of rhabdomyolysis was similar in patients with liver
metastases at baseline (0.8 %) with respect to those without liver
metastases at baseline (0.9 %)
d This drug can induce serotoninergic syndrome, and this syndrome
may secondarily induce rhabdomyolysis
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Analyses were performed to determine potential risk fac-
tors; these included demographic data, indication, dose,
prior history (hepatitis, liver metastasis, fatigue, myalgia,
weakness), concomitant treatment, and laboratory status.
Two multivariate logistic regression, stepwise selection
models were evaluated. The ﬁrst model included all cases
(n = 20) and explored all the aforementioned covariates,
baseline laboratory status, and laboratory data prior to the
occurrence of rhabdomyolysis. The second model included
cases of rhabdomyolysis that occurred in Cycle 2 and
onwards (n = 17) and explored all covariates, with worst
laboratory disorders reported in Cycle 1 (Table 4).
The ﬁrst model selected only one covariate: the theo-
retical trabectedin dose per week, with an odds ratio
(OR) = 1.008 (95 % CI 1.001–1.016). According to this
multivariate model, the probability for non-occurrence of
rhabdomyolysis with trabectedin at the recommended dose
Table 3 Cases of
rhabdomyolysis and creatine
phosphokinase increases
(without acute renal failure)
during treatment with
trabectedin in cancer patients:
cycles, regimens, relationship,
concomitant medical conditions,
and outcome
Cutoff, September 17, 2010
ARF acute renal failure, CPK
creatine phosphokinase, d day,
NCI-CTCAE National Cancer
Institute Common Toxicity
Criteria for Adverse Events,
PLD pegylated liposomal
doxorubicin, q3wk every
3 weeks, q4wk every 4 weeks
a CPK increases (without acute
ARF) reported as serious
adverse events (any grade) in
the Pharmacovigilance
database, or as severe (grade 3
or 4 according to NCI-CTCAE)
in the Clinical Trials database
b Data are shown for the 75
cases of rhabdomyolysis and the
58 cases of CPK increases
without ARF. The total of
patients treated for each variable
was not available in
marketplace and compassionate
use in order to calculate the
respective incidence
c Unknown: neutropenia
(n = 18), febrile neutropenia
(n = 23), and hepatic
dysfunction (n = 25)
d Unknown: febrile neutropenia
(n = 12) and hepatic
dysfunction (n = 11)
Rhabdomyolysis CPK increases (without ARF)
a
n = 75
b % n = 58
b %
Cycle of event onset
1 10 13.3 7 12.1
2 43 57.3 12 20.7
3 10 13.3 8 13.8
4 2 2.7 4 6.9
5 2 2.7 6 10.3
[5 2 2.7 14 24.1
Unknown 6 8.0 7 12.1
Trabectedin regimen
Weekly – – 4 6.9
0.38 mg/m
2 d 9 5 q3wk 1 1.3 – –
0.4 mg/m
2 q3wk 1 1.3 – –
0.8 mg/m
2 d1, 8, d15 q4wk 1 1.3 – –
1.1 mg/m
2 q3wk (plus PLD) 1 1.3 – –
1.1 mg/m
2 q3wk 2 2.7 – –
1.2 mg/m
2 q3wk 3 4.0 – –
1.3 mg/m
2 q3wk 3 4.0 – –
1.5 mg/m
2 q3wk 35 46.7 – –
q3wk (dose unknown) 16 21.3 35 60.3
Unknown (dose and regimen) 12 16.0 19 32.8
Relationship with trabectedin treatment
Related 70 93.4 50 86.2
Doubtful 1 1.3 2 3.4
Not assessed 3 4.0 – –
Not related – – 3 5.2
Unknown 1 1.3 3 5.2
Concomitant medical conditions
Neutropenia 53 70.7 25 43.1
Febrile neutropenia 20
c 26.7 1
d 1.7
Hepatic dysfunction 50
c 66.7 30
d 51.7
Dialysis 20 26.7 – –
Outcome of the event
Fatal 31 41.3 – –
Recovered 25 33.3 40 69.0
Recovered with sequelae 4 5.3 1 1.7
Recovering 2 2.7 – –
Not recovered – – 3 5.2
Unknown 13 17.3 14 24.1
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2 q3wk; i.e.,
0.5 mg per week) is 98.7 % and with the regimen approved
in ovarian cancer (1.1 mg/m
2 q3wk; i.e., 0.37 mg per
week; in combination with PLD) is 99.6 %.
The second model selected 2 covariates: myelosup-
pression (neutropenia and thombocytopenia) in Cycle 1
(OR = 0.078; 95 % CI 0.024–0.258), and transaminase
elevation (ALT or AST) in Cycle 1 (OR = 0.331; 95 % CI
0.120–0.917) (Table 4). The probability of developing
rhabdomyolysis in Cycle 2 or onwards was higher in those
patients who had both grade 3/4 myelosuppression and
transaminase elevation in Cycle 1. This underlines the need
to modify the dose of trabectedin in subsequent cycles if
signiﬁcant liver impairment is observed or does not resolve
prior to repeat dosing, as recommended in the Summary of
Product Characteristics of trabectedin. These results also
support that strict laboratory controls, fulﬁllment of criteria
for treatment delay or continuation, and dose adjustment
guidelines are extremely important to avoid unacceptable
toxicities.
However, the model failed to identify deﬁnite predis-
posing factors for rhabdomyolysis. The spatial distribution
according to a multiple correspondence analysis of the
values of the 2 variables included in the multivariate
logistic regression model (Fig. 1) accurately predicted the
absence of rhabdomyolysis from Cycle 2 onwards in those
cases without grade 3/4 myelotoxicity or transaminases
increases in Cycle 1 (i.e., the ‘‘no grade 3/4’’ categories
were grouped far from the ‘‘rhabdomyolysis’’ area). Nev-
ertheless, the model could not predict either the occurrence
of rhabdomyolysis in the presence of one or several of the
aforementioned severe disorders (grade 3/4 laboratory
abnormalities).
Cases of rhabdomyolysis and pharmacokinetic analysis
The main PK variables [CL, Cmax, and AUC (population)]
were explored in relationship with the occurrence of
rhabdomyolysis (Table 5). A total of 11 of 900 evaluable
patients with available PK data had rhabdomyolysis. In a
multivariate logistic regression analysis, only the CL
resulted signiﬁcant (p\0.0001) (i.e., higher probability of
rhabdomyolysis in case of lower trabectedin CL), but was
not identiﬁed as a risk factor, since most patients with low
CL did not develop rhabdomyolysis (Fig. 2). In addition,
the exposure PK parameters evaluated (Cmax and AUC) did
not show any signiﬁcant relationship with the development
of this event.
Discussion
This comprehensive safety analysis shows rhabdomyolysis
to be an uncommon event during trabectedin treatment,
with an overall incidence of 0.7 %. Apart from the treat-
ment with trabectedin, confounding factors for the devel-
opment of rhabdomyolysis were identiﬁed: concomitant
treatments (atorvastatin, carbidopa/levodopa), hypothy-
roidism, muscular trauma, or infection (sepsis and severe
pneumonia).
Rhabdomyolysis usually occurred during the ﬁrst 2
cycles of treatment (53 of 75; 70.7 %), with only 2 cases
after[5 cycles, which rules out a cumulative adverse effect
of trabectedin. In this patient population, rhabdomyolysis
was commonly accompanied by the presence of neutro-
penia and abnormal liver function tests, which suggests that
this adverse reaction could be the result of intolerance to
trabectedin. Multivariate analyses showed a higher proba-
bility of rhabdomyolysis in Cycle 2 or onwards in patients
with concomitant grade 3/4 neutropenia and thrombocy-
topenia, and grade 3/4 transaminase increase in the ﬁrst
treatment cycle, but these disorders were not identiﬁed as
risk or predictive factors of rhabdomyolysis, and they
rather represented co-morbidities, which support the
hypothesis of an uncommon trabectedin idiosyncratic
reaction in patients who develop rhabdomyolysis, which
may predispose them to develop other severe adverse
reactions. In fact, transaminases increases are common in
Table 4 Covariates selected in multivariate logistic regression (stepwise variable selection) analyses of rhabdomyolysis cases occurred in
clinical trials with trabectedin in cancer patients
Parameter Class p Value OR (95 % CI)
Covariates selected when including all 20 rhabdomyolysis cases found in clinical trials
Theoretical trabectedin dose per week (lg/week) – 0.0270 1.008 (1.001–1.016)
Covariates selected when including rhabdomyolysis cases occurred from Cycle 2 onwards (n = 17) and peak/nadirs of laboratory data occurred
in Cycle 1 in clinical trials
Myelosuppression Grade 0–2 versus grade 3–4 \0.0001 0.078 (0.024–0.258)
Transaminases increase Grade 0–2 versus grade 3–4 0.0334 0.331 (0.120–0.917)
The constant was statistically signiﬁcant in the two models
Degree of freedom was 1 for all selected covariates
CI conﬁdence interval, OR odds ratio
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retrospective review of 215 cases of rhabdomyolysis with
CPK C 1,000 IU/l and normal liver function showed
abnormal AST in 93.1 % (95 % CI 88.7–95.8 %) and
abnormal ALT in 75.0 % (95 % CI 68.7–80.2 %) of these
patients [23]. Rhabdomyolysis can be further complicated
with sepsis and multi-organ failure; then, neutropenia may
also be a frequent concomitant adverse event [10, 15].
These results also support that appropriate laboratory
controls and fulﬁllment of criteria for continuation of
treatment and dose adjustment guidelines are extremely
important to prevent the development of severe adverse
reactions. In 2003, a retrospective evaluation based on data
from early clinical trials suggested that premedication with
dexamethasone improved hepatic tolerability to trabect-
edin, and since then, premedication with corticosteroids
has been mandatory [4, 11, 13, 18]. In addition, close
monitoring of hematological parameters, liver function and
CPK were recommended weekly during the ﬁrst two
cycles. Criteria for treatment continuation or dose adjust-
ment according to these laboratory parameters were
implemented. As a result, the current analysis shows a
decrease in the incidence of rhabdomyolysis in clinical
trials from 1.0 % prior to 2003 to 0.7 % since 2003. An
exponential regression to adjust the percentage of rhabdo-
myolysis cases per year up to the last available information
was performed. A statistically negative independent
parameter (p = 0.0139) was associated indicating that the
incidence of this adverse event has decreased throughout
the years. In addition, 4 of the rhabdomyolysis cases for
which full information was available occurred in patients in
whom criteria for re-treatment and dose adjustment were
not followed according to current trabectedin administra-
tion guidelines.
Multivariate analyses showed the theoretical trabectedin
dose per week to be statistically signiﬁcant. The PK anal-
ysis showed no apparent relationship between drug expo-
sure parameters (Cmax and AUC) and occurrence of
rhabdomyolysis but the logistic model of PK analysis
showed that low CL was related. However, further PK
predictive analysis showed that only a very small per-
centage of patients with low CL from the analyzed sample
actually developed rhabdomyolysis. A signiﬁcant number
of patients with PK available for the present analysis were
treated in phase I clinical trials, in which the dose admin-
istered varied signiﬁcantly (from 0.024 to 1.8 mg/m
2). This
fact may explain why a relationship with CL was found,
but not with AUC. Low trabectedin CL could reﬂect a
condition in the patient (liver impairment, protein levels,
polymorphisms affecting transporters) that had more impact
on the probability of developing rhabdomyolysis than the
trabectedin AUC itself, for example, by reﬂecting tissue,
rather than plasma exposure. Therefore, it seems that a non-
predictable individual sensitivity (e.g., an idiosyncratic
reaction to the drug) could lead to this rare event.
Trabectedin is eliminated through hepatic metabolism
and CYP3A4 is the principal responsible enzyme. As a
high number of drugs are also metabolized by this enzyme,
interactions with multiple concomitant drugs could arise.
According to in vitro data, trabectedin exposure could
be increased in the presence of CYP3A4 inhibitor [3].
Therefore, co-administration of trabectedin with potent
Fig. 1 Multiple
correspondence analysis
between grade 3/4
myelotoxicity (neutrophils and
platelets) and grade 3/4
transaminases occurred in
Cycle 1 and occurrence of
rhabdomyolysis from Cycle 2
onwards in clinical trials
evaluating trabectedin
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123CYP34A inhibitors should be avoided or, if this is not
possible, closer patient monitoring is required. In this
analysis, 8 patients with rhabdomyolysis had concomitant
administration of CYP3A4 inhibitors (verapamil, diltia-
zem, amiodarone, lercanidipine, aprepitant, and clarithro-
mycin). Additionally, 8 patients had prior or concomitant
liver conditions that could have affected the hepatic
metabolism of trabectedin.
Rhabdomyolysis is a treatable disorder, and patient
prognosis depends on early recognition and immediate
treatment, such as parenteral hydration, urine alkaliniza-
tion, and dialysis [5, 14]. In this analysis, dialysis was
reported in 26.7 % of cases. As most patients had advanced-
stage cancer, a high number of them refused treatment for
this event or they were not considered candidates for treat-
ment, which likely contributed in some cases to the fatal
outcome. Late treatment start once the event had worsened
may have also contributed to fatal prognosis. Treatment with
trabectedin should be discontinued when rhabdomyolysis is
diagnosed.
Creatine phosphokinase increases have been usually
observedin20–30 %ofpatientstreatedwithtrabectedin[4,8,
9], although most of them are grade 1/2 laboratory abnor-
malities without clinical signiﬁcance. In order to take a con-
servative approach, the present analysis also included cases
reporting serum CPK increase in the absence of ARF and
considered clinically relevant, that is, severe (grade 3/4) and
serious (any grade) adverse events. Clinically relevant CPK
increases were also uncommon (0.4 % in the total of treated
patients), and their onset appeared during the ﬁrst 3 cycles of
treatment in almost half of the cases. These events were
associatedwithneutropeniain41.3 %ofcases,andabnormal
liver function was reported in about half of cases (51.7 %).
Overall,thisappearedasanincidentalﬁnding,withoutclinical
impact, and with a good prognosis.
In conclusion, this comprehensive safety analysis con-
ﬁrms rhabdomyolysis and clinically relevant (severe or
serious) CPK increases without ARF to be uncommon
events associated with trabectedin treatment. Multivariate
and PK analyses did not show any predictive or high risk
factor of developing rhabdomyolysis, thus suggesting the
event as a possible idiosyncratic reaction. Prompt diagnosis
and management of rhabdomyolysis is crucial for its res-
olution. Close patient monitoring, especially during the
ﬁrst 3 cycles, and adequate treatment adjustment in cases
of severe myelosuppression and liver dysfunction are
mandatory. Implementation of corticosteroid pre-treatment
and close monitoring with dose adjustments according to
myelosuppression, liver function abnormalities, and CPK
levels have contributed to a reduction in the incidence of
rhabdomyolysis and are currently included in the guide-
lines for trabectedin administration.
Table 5 Main trabectedin pharmacokinetic parameters in absence or
presence of rhabdomyolysis
Rhabdomyolysis
a CL (l/h) Cmax
(ng/ml)
AUC
(h ng/ml)
Yes
n 11 11 11
Mean 18.91 8.49 145.29
SD 5.99 10.08 71.66
Median 19.12 6.63 135.73
Min–Max 8.80–32.94 0.80–31.10 26.93–320.43
No
n 889 889 889
Mean 38.15 7.71 59.28
SD 15.79 25.98 45.14
Median 36.16 3.83 48.20
Min–Max 4.50–110.07 0.04–487.97 1.03–395.03
Multivariate logistic regression analysis
b
p Value \0.0001 0.3837 0.6738
OR (95 % CI) 0.845
(0.819–0.871)
––
AUC area under the curve, Cmax maximum plasma concentration,
CI conﬁdence interval, CL clearance, Max maximum, Mean arith-
metic mean, Min minimum, OR odds ratio, PK pharmacokinetic, SD
standard deviation
a In those cases with PK data available in more than one cycle (ﬁrst
or second), only one PK proﬁle per patient was selected for matching
the rhabdomyolysis cases
b No statistically signiﬁcant association between AUC and Cmax of
trabectedin and the occurrence of rhabdomyolysis was observed
Fig. 2 Frequencies for clearance (CL) in presence/absence of rhab-
domyolysis. RBD = 0( blue histograms) = absence of rhabdomyoly-
sis. RBD = 1( green histograms) = presence of rhabdomyolysis
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